Skip to Content
Søk Menu

HER2-negative Breast Cancer – A Pathologist’s Perspective

/ Gilead
Bröstcancer
Peeter Karihtala

The Clinical Value of Immuno-Oncological Treatments in Early Breast Cancer

/ Peeter Karihtala
Bröstcancer Play the Video

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
BröstcancerESMO25NBCN
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
BröstcancerESMO25NBCN Play the Video
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
BröstcancerESMO25NBCN Play the Video

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
BröstcancerESMO25NBCN

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

/ Jan Andreasen
BröstcancerESMO25NBCN
Alan Celik

Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

/ Alan Celik
Bröstcancer Play the Video
Dimitrios Salgkamis

ESMO Breast Cancer 2025: Potential Biomarkers Linked to Hematologic Toxicity

/ Dimitrios Salgkamis
BröstcancerNBCN Play the Video
Anders Winther Mølby Nielsen

New Data Support Boost in ER-/HER2- Breast Cancer

/ Anders W. Mølby Nielsen
BröstcancerNBCN Play the Video
Birgitte Offersen

Unexpected Mortality in Hypofractionated Loco-Regional Breast Cancer Radiotherapy

/ Birgitte Vrou Offersen
BröstcancerNBCN Play the Video
Christoffer Vannas

Swedish Insights Into Alpelisib Treatment for Metastatic Breast Cancer with PIK3CA Mutation

/ Christoffer Vannas
BröstcancerNBCN Play the Video
Hent flere
Back to top